THE EFFICACY AND SAFETY OF CANGRELOR FOR PATIENTS UNDERGOING SINGLE VESSEL VERSUS MULTI VESSEL PERCUTANEOUS CORONARY INTERVENTION: INSIGHTS FROM THE CHAMPION PHOENIX TRIAL
2018
The intravenous, rapidly acting P2Y12 inhibitor cangrelor reduces the rate of ischemic events during percutaneous coronary intervention (PCI) with no significant increase in severe bleeding. This study aimed to evaluate the efficacy and safety of cangrelor in patients treated with single vessel (SV
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI